Lead Product(s) : Erdosteine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recipharm’s Proprietary Molecule Erdosteine has been Positively Tested As Part of COVID-19 Treatment
Details : The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Erdosteine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
